Meaverin

Mepivacaine Hydrochloride, the active ingredient in Meaverin, is a local anesthetic presented as a sterile solution for epidural, intradermal and intravenous use. It provides reversible nerve blockade for minor surgical, dental and regional analgesia procedures in adult patients. GNH USA supplies Meaverin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meaverin is a local anesthetic that acts on peripheral nerve sodium channels to produce reversible loss of sensation. - Minor surgical procedures: enables pain‑free operating fields for brief surgeries. - Dental procedures: provides infiltration anesthesia for routine dental work. - Epidural analgesia: delivers regional pain relief during labor or postoperative periods. - Diagnostic procedures: allows surface anesthesia for skin biopsies or minor examinations.

Adverse reactions may occur following administration of Meaverin.

Common Side Effects: - Injection site pain: mild discomfort at the injection site. - Transient numbness: temporary loss of sensation in the treated area. - Mild dizziness: brief sensation of light‑headedness.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm that may require monitoring. - Seizure: rare central nervous system excitation. - Methemoglobinemia: abnormal hemoglobin that reduces oxygen delivery.

Use Meaverin with caution and observe recommended safety measures. - Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics. - Cardiovascular status: apply cautiously in patients with conduction disorders. - Dosage limits: adhere to the maximum recommended dose set by the prescriber. - Concurrent CNS depressants: monitor for additive sedative effects. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Consider potential drug interactions when using Meaverin.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): may enhance cardiotoxicity. - Beta‑blockers: increase risk of bradycardia.

Moderate Interactions (Monitor Closely): - General anesthetics: may potentiate central nervous system depression. - Opioids: additive sedative effect may occur. - Monoamine oxidase inhibitors: possible increased neurotoxicity.